A pilot study assessing the potential role of non-CD133 colorectal cancer stem cells as biomarkers

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 231-240

  Langan, Russell C ^a   Mullinax, John E ^a   Ray, Satyajit ^a   Raiji, Manish T ^a   Schaub, Nicholas ^a   Xin, Hong Wu ^a   Koizumi, Tomotake ^a   Steinberg, Seth M ^a   Anderson, Andrew ^a   Wiegand, Gordon ^a   Butcher, Donna ^b   Anver, Miriam ^b   Bilchik, Anton J ^c   Stojadinovic, Alexander ^d,e   Rudloff, Udo ^a   Avital, Itzhak ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e Uniformed Services University of the Health Sciences   (United States)

^f Bon Secours Cancer Institute   (United States)

Author keywords

Biomarkers; Cancer recurrence; Cancer stem cells; Colon cancer; Lymph node; Overall survival; Prognosis; Staging

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA1 INTEGRIN; CD133 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; PROTEIN ALDHIAI; PROTEIN ALDHIBI; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER STEM CELL; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION;

EID: 84872245125     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.4542     Document Type: Article

References (42)

1. Siegel R, Ward E, Brawley O, et al: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36
2. Bilchik AJ, DiNome M, Saha S, et al: Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg 2006; 141:527-33.
3. Manfredi S, Bouvier AM, Lepage C, et al: Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006;93:1115-22
4. Galizia G, Gemei M, Del Vecchio L, et al: Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in pa-tients with colorectal cancer. Arch Surg 2012;147:18-24
5. Falcone A, Ricci S, Brunetti I, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6
6. Wolpin BM, Meyerhardt JA, Mamon HJ, et al: Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007;57:168-85
7. Tejpar S, Bertagnolli M, Bosman F, et al: Prognostic and predictive biomarkers in resected colon cancer: current status and future per-spectives for integrating genomics into biomarker discovery. On-cologist 2010;15:390-404
8. Gryfe R, Kim H, Hsieh ET, et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77
9. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatel-lite-instability status as a predictor of benefit from fluoroura-cil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57
10. Sinicrope FA, Sargent DJ: Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 2009;21:369-73
11. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65
12. Ahnen DJ, Feigl P, Quan G, et al: Ki-ras mutation and p53 overex-pression predict the clinical behavior of colorectal cancer: a South-west Oncology Group study. Cancer Res 1998;58:1149-58
13. O'Brien CA, Pollett A, Gallinger S, et al: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Na-ture 2007;445:106-10
14. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5
15. Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68
16. Xin HW, Hari DM, Mullinax JE, et al: Tumor-initiating la-bel-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells 2012;30:591-8
17. Avital I, Moreira AL, Klimstra DS, et al: Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells 2007;25:2903-9
18. Hari D, Xin HW, Jaiswal K, et al: Isolation of live label-retaining cells and cells undergoing asymmetric cell division via nonrandom chromosomal cosegregation from human cancers. Stem Cells Dev 2011;20:1649-58
19. Papailiou J, Bramis KJ, Gazouli M, et al: Stem cells in colon cancer. A new era in cancer theory begins. Int J Colorectal Dis 2011;26:1-11
20. Vaiopoulos AG, Kostakis ID, Koutsilieris M, et al: Colorectal cancer stem cells. Stem Cells 2012;30:363-71
21. Subramaniam D, Ramalingam S, Houchen CW, et al: Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev Med Chem 2010;10:359-71
22. Marquardt JU, Thorgeirsson SS: Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin Liver Dis 2010;30:26-34
23. Lugli A, Iezzi G, Hostettler I, et al: Prognostic impact of the expres-sion of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010;103:382-90
24. Pilati P, Mocellin S, Bertazza L, et al: Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resec-tion for colorectal liver metastasis. Ann Surg Oncol 2012;19:402-8
25. Zlobec I, Gunthert U, Tornillo L, et al: Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology 2009;55:564-75
26. Willis ND, Przyborski SA, Hutchison CJ, et al: Colonic and colo-rectal cancer stem cells: progress in the search for putative bi-omarkers. J Anat 2008;213:59-65
27. Deng S, Yang X, Lassus H, et al: Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010;5:e10277
28. Dalerba P, Dylla SJ, Park IK, et al: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007;104:10158-63
29. Kemper K, Grandela C, Medema JP: Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010;1:387-95
30. Zou J, Yu XF, Bao ZJ, et al: Proteome of human colon cancer stem cells: a comparative analysis. World J Gastroenterol 2011;17:1276-85
31. Mulder JW, Kruyt PM, Sewnath M, et al: Colorectal cancer progno-sis and expression of exon-v6-containing CD44 proteins. Lancet 1994;344:1470-2
32. Wielenga VJ, van der Voort R, Mulder JW, et al: CD44 splice vari-ants as prognostic markers in colorectal cancer. Scand J Gastroen-terol 1998;33:82-7
33. Coppola D, Hyacinthe M, Fu L, et al: CD44V6 expression in human colorectal carcinoma. Hum Pathol 1998;29:627-35
34. Patriarca C, Macchi RM, Marschner AK, et al: Epithelial cell adhe-sion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 2012;38:68-75
35. Gastl G, Spizzo G, Obrist P, et al: Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356:1981-2
36. Prince S, Zeidman A, Dekel Y, et al: Expression of epithelial cell adhesion molecule in gallbladder carcinoma and its correlation with clinicopathologic variables. Am J Clin Pathol 2008;129:424-9
37. Gosens MJ, van Kempen LC, van de Velde CJ, et al: Loss of mem-branous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 2007;20:221-32
38. Patel BB, Yu Y, Du J, et al: Age-related increase in colorectal cancer stem cells in macroscopically normal mucosa of patients with ade-nomas: a risk factor for colon cancer. Biochem Biophys Res Com-mun 2009;378:344-7
39. Weichert W, Knosel T, Bellach J, et al: ALCAM/CD166 is overex-pressed in colorectal carcinoma and correlates with shortened pa-tient survival. J Clin Pathol 2004;57:1160-4
40. Choi D, Lee HW, Hur KY, et al: Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colo-rectal adenocarcinoma. World J Gastroenterol 2009;15:2258-64
41. Lim SC, Oh SH: The role of CD24 in various human epithelial neo-plasias. Pathol Res Pract 2005;201:479-86
42. Weichert W, Denkert C, Burkhardt M, et al: Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005;11:6574-81